TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31571526
Drug: Dynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic treatment regimen for increasing motivation to attend treatments
Study: 26291817
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg intravaginal progesterone
Study: 26291817
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg intravaginal progesterone
Study: 21836549
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving weekly encouragement to remain smoke free and routine breastfeeding support.
Study: 21162922
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection of ropivacaine, morphine and epinephrine
Study: 17923867
Drug: Intensive CEP
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive CEP (C 1800 mg m(‐2), E 50 mg m(‐2), P 75 mg m(‐2) with filgrastim 5 mug kg(‐1) per day x 10 days)
Study: 17923867
Drug: Standard CEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CEP (C 500 mg m(‐2), E 50 mg m(‐2), P 75 mg m(‐2))
Study: 29706210
Drug: Amoxicillin (antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (antibiotic prophylaxis)
Study: 20177681
Drug: 4,000 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000 IU/day low molecular weight heparin (LMWH) prophylaxis
Study: 12935823
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T levels >0.1 microg/L
Study: 12935823
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T levels <=0.1 microg/L
Study: 12935823
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T cutoff value 0.03 microg/L
Study: 12935823
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T cutoff value 0.01 microg/L
Study: 12935823
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T cutoff value <=0.01 microg/L
Study: 10673519
Drug: G-CSF (filgrastim)
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (filgrastim) administered at a daily dose of 5 microg/kg after two courses of intensive consolidation chemotherapy (ICC)
Study: 8790153
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (Duraflo II) and reduced systemic heparinization (ACT > 250s)
Study: 8790153
Drug: Non-coated circuits
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-coated circuits and standard heparin administration (ACT > 480s)
Study: 7969680
Drug: 3H‐ANG(1‐8) infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3H‐ANG(1‐8) infusion (0.5, 2.0, and 2.5 ng/kg/min)
Study: 3593628
Drug: Ibopamine administered
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine administered immediately after a meal
Study: 3593628
Drug: Ibopamine administered
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine administered 2 hours after a meal
Study: 3593628
Drug: Ibopamine administered
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine administered 0.5 hours before a meal
Study: 3593628
Drug: Ibopamine administered
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine administered 3 hours after a meal
Study: 3593628
Drug: Ibopamine administered
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine administered in fasting state
Study: 21957976
Drug: Telmisartan-based plus
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan-based plus simvastatin therapy
Study: 21957976
Drug: Telmisartan-based monotherapy
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan-based monotherapy
Study: 16680067
Drug: E2/NETA (17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (17beta‐estradiol 2 mg plus norethisterone acetate 1 mg)
Study: 16680067
Drug: Low E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low E2/NETA (17beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg)
Study: 1799474
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b 5 million units subcutaneously three times weekly until progression or relapse
Study: 6656960
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (radiotherapy with chemotherapy: methotrexate and 5-fluorouracil)
Study: 6656960
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (radiotherapy with chemotherapy)
Study: 28648704
Drug: Bicruciate-stabilized implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicruciate-stabilized implant
Study: 28648704
Drug: Posterior-stabilized implant
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior-stabilized implant
Study: 25889509
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 μg/d L-selenomethionine)
Study: 17726586
Drug: Intra-articular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular ketamine (0.25 mg S-(+)-ketamine/kg body weight in 10 ml 0.9% NaCl)
Study: 17726586
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.25 mg S-(+)-ketamine/kg body weight)
Study: 17726586
Drug: Intra-articular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular bupivacaine (10 ml 0.25% bupivacaine)
Study: 17726586
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 ml 0.9% NaCl)
Study: 9562230
Drug: Sertindole 20
Normalized name: sertindole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 20 mg daily
Study: 7651057
Drug: N-acetylcysteïne (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteïne (NAC) 3 x 600 mg per day for 5 days, starting 5 or 10 days after Photofrin
Study: 2689182
Drug: Diltiazem (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (360 mg per day orally)
Study: 2689182
Drug: Methotrexate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (4 g.m-2 body surface area)
Study: 766724
Drug: Laxogas gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxogas gas producing suppositories
Study: 31917843
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV every 3 weeks for up to 8 cycles, starting within 21 days of post-ASCT discharge)
Study: 24699943
Drug: Integrated and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated and culturally attuned CBT group treatment (n = 18)
Study: 10969346
Drug: Genotypic guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypic guided treatment
Study: 9428983
Drug: Biapenem 500
Normalized name: biapenem
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem 500 mg administered intravenously over 30 min
Study: 9428983
Drug: Biapenem administered
Normalized name: biapenem
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem administered after haemodialysis or in double the dose on haemodialysis days
Study: 7679869
Drug: Benazepril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (20 mg) and Hydrochlorothiazide (50 mg) for 3 months
Study: 7679869
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg) for 3 months
Study: 29194772
Drug: Aspirin 1
Normalized name: aspirin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1 mg/kg
Study: 29194772
Drug: Clopidogrel 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 2 mg/kg
Study: 29194772
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Aspirin + Clopidogrel)
Study: 23424159
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) 20 mg daily
Study: 27473139
Drug: Interferon β-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon β-1b (IFN‐β‐1b) 250 μg subcutaneous every other day
Study: 19815651
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (70 mg/m² on days 1, 8, and 15) combined with carboplatin (AUC = 6 on day 1)
Study: 19815651
Drug: Standard paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard paclitaxel (200 mg/m² on day 1) combined with carboplatin (AUC = 6 on day 1)
Study: 19101902
Drug: Triamcinolone 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone 1% ointment
Study: 19101902
Drug: Water-based gel
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based gel (control)
Study: 10084064
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low molecular weight heparin (OP 2000)
Study: 7486089
Drug: Epinephrine 7.5
Normalized name: bupivacaine HCl/epinephrine 7.5 mg/mL (0.75 %)-1:200,000 INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 7.5 group (3 mL 1.5% lidocaine containing 7.5 micrograms epinephrine)
Study: 7486089
Drug: Epinephrine 15
Normalized name: lidocaine HCl/epinephrine 15 mg/mL (1.5 %)-1:200,000 INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 15 group (3 mL 1.5% lidocaine containing 15 micrograms epinephrine)
Study: 7486089
Drug: Epinephrine 22.5
Normalized name: epinephrine 22.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 22.5 group (3 mL 1.5% lidocaine containing 22.5 micrograms epinephrine)
Study: 7486089
Drug: Saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group (3 mL normal saline)
Study: 399436
Drug: Coccinia indica
Normalized name: COCCINIA INDICA FRUIT EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coccinia indica preparation (experimental group)
Study: 27327849
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (sugar-free gum every 2 hours for 20 minutes from the end of drinking 2 L of PEG to the beginning of colonoscopy)
Study: 27327849
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 L of PEG before colonoscopy)
Study: 23677743
Drug: Finely crushed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finely crushed ORF tablets
Study: 23677743
Drug: Coarsely crushed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coarsely crushed ORF tablets
Study: 23677743
Drug: Finely crushed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finely crushed OC tablets
Study: 20137493
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy without antibiotic
Study: 11426771
Drug: Colforsin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colforsin treatment (0.5 microg.kg(‐1).min(‐1) for 6 hours)
Study: 11426771
Drug: No colforsin
Normalized name: Colforsin
DrugBank: Colforsin (DB02587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No colforsin treatment (control)
Study: 2597599
Drug: Benfluorex (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfluorex (three tablets/day) for six months (Group A)
Study: 5570647
Drug: Phenobarbitone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone administration alongside methyldopa
Study: 26549958
Drug: Naikan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naikan therapy (2 hours daily, 5 days a week for 4 weeks)
Study: 26549958
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication and inpatient rehabilitative treatment (Control)
Study: 10392328
Drug: Etodolac immediate
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac immediate release (IR) 200 mg
Study: 10392328
Drug: Etodolac immediate
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac immediate release (IR) 400 mg
Study: 10392328
Drug: Etodolac extended
Normalized name: Etodolac Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac extended release (ER) 400 mg
Study: 10392328
Drug: Etodolac extended
Normalized name: Etodolac Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac extended release (ER) 1200 mg
Study: 6394758
Drug: MTX 10
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 10 mg
Study: 6394758
Drug: MTX 25
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 25 mg
Study: 6394758
Drug: MTX 10
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 10 mg (after 6 weeks for Group 1)
Study: 6394758
Drug: MTX 25
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 25 mg (after 6 weeks for Group 2)
Study: 6394758
Drug: MTX 25
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 25 mg (after 6 weeks for Group 3)
Study: 21298835
Drug: Packed rice-oral
Normalized name: red yeast rice Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packed rice-oral rehydration solution (R-ORS)
Study: 21298835
Drug: Glucose-based oral
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based oral rehydration solution (G-ORS)
Study: 17621994
Drug: Soyfem (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soyfem (standardized isoflavones extract) 52-104 mg/24h, administered as 1 or 2 tablets twice a day
Study: 3890640
Drug: Initial phase
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial phase of chemotherapy (streptomycin, isoniazid, rifampicin, and pyrazinamide)
Study: 3890640
Drug: Continuation phase
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation phase of chemotherapy
Study: 26998705
Drug: Control-Intervention (CI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control-Intervention (CI) group received hourly alerts to get up during work hours
Study: 26998705
Drug: Control-Control (CC)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control-Control (CC) group maintained normal behaviors
Study: 22223819
Drug: Rituximab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (4 weekly infusions of 375 mg/m(2))
Study: 19192455
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (36 mg/day, 54 mg/day, 72 mg/day, 90 mg/day)
Study: 19192455
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (maximally effective dose)
Study: 12356630
Drug: BQ‐123 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ‐123 (selective blocker of ET(A) receptors)
Study: 12356630
Drug: ET‐1 (exogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET‐1 (exogenous infusion)
Study: 12356630
Drug: BQ‐123 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ‐123 and BQ‐788 (coinfusion of selective blockers of ET(A) and ET(B) receptors)
Study: 10471426
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 100 mg BID (2 intravenous infusions followed by 6 days' oral treatment)
Study: 10471426
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 200 mg BID or higher
Study: 10471426
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 400 mg BID
Study: 10471426
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 500 mg BID
Study: 10471426
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 600 mg BID
Study: 8938005
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of frame aspect ratio and pictorial depth
Study: 31553228
Drug: Toutongning (TTN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toutongning (TTN) capsule (1200 mg, three times daily)
Study: 26817912
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus oxaliplatin (capecitabine 1000 mg/m bid on days 1-10 and oxaliplatin 85 mg/m on day 1, every 2 weeks) followed by docetaxel plus capecitabine (docetaxel 30 mg/m on days 1 and 8, capecitabine 825 mg/m bid on days 1-14, every 3 weeks)
Study: 22241923
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab and low-dose transpupillary thermotherapy (TTT)
Study: 22241923
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab and low-dose TTT
Study: 20631453
Drug: iv cibenzoline
Normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv cibenzoline (70 mg)
Study: 20631453
Drug: iv disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv disopyramide (50 mg)
Study: 15907672
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (antibiotics, corticosteroids, 0.9% sodium chloride solution, local decongestants, n=21)
Study: 15907672
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n=21)
Study: 10180750
Drug: Fluconazole (FLU)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole (FLU) administered intravenously
Study: 10180750
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AMB) administered intravenously
Study: 10180750
Drug: Fluconazole (FLU)
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole (FLU) administered intravenously for 7 days then orally
Study: 2651177
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg pirprofen capsules
Study: 27815771
Drug: Multicomponent inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent inpatient program (4+4 days) consisting of Acceptance and Commitment Therapy, physical training, and work-related problem-solving.
Study: 27815771
Drug: Outpatient program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient program (6 sessions during 6 weeks) primarily consisting of Acceptance and Commitment Therapy.
Study: 10214566
Drug: Surgical procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical procedure without ADCON-L (Control)
Study: 7717485
Drug: Lignocaine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 0.5 mg.kg‐1
Study: 7717485
Drug: Lignocaine 1
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1 mg.kg‐1
Study: 31812307
Drug: Phenytoin spray
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin spray 2% for 8 weeks
Study: 31812307
Drug: Phenytoin spray
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin spray 2%
Study: 12220747
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment from family physician
Study: 8560162
Drug: N-acetyl-aspartyl-glutamic acid
Normalized name: acetyl glutamic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-aspartyl-glutamic acid (NAAGA) nasal spray, one puff per nostril, four times daily, for 3 weeks
Study: 8560162
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) nasal spray, one puff per nostril, four times daily, for 3 weeks
Study: 8560162
Drug: N-acetyl-aspartyl-glutamic acid
Normalized name: acetyl glutamic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-aspartyl-glutamic acid (NAAGA) nasal spray
Study: 8560162
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) nasal spray
Study: 2672925
Drug: Amiprilose HCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiprilose HCl, 6 g/d
Study: 30747908
Drug: NKTR-181 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-181 100 to 400 mg every 12 hours
Study: 25064487
Drug: Hand massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand massage therapy
Study: 22130790
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation of griseofulvin with TPGS and ethanol
Study: 22130790
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation of griseofulvin
Study: 19394033
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution plus racecadotril (OR + R)